No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INCR InterCure
- 3.620
- +0.500+16.03%
Close May 6 16:00 ET
- 3.650
- +0.030+0.83%
Post 18:01 ET
164.97MMarket Cap29.19P/E (TTM)
3.720High3.320Low163.28KVolume3.350Open3.120Pre Close571.95KTurnover0.56%Turnover Ratio13.56P/E (Static)45.57MShares3.72052wk High1.20P/B106.56MFloat Cap0.99052wk Low--Dividend TTM29.44MShs Float8.770Historical High--Div YieldTTM12.81%Amplitude0.990Historical Low3.502Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
InterCure Reports FY Results
Intercure Ltd. Files April SEC Report
Press Release: InterCure Announces FY2023 Results: Revenue of NIS 356 Million and Adjusted EBITDA of NIS 61 Million
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million -- Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Intercure Ltd. Submits SEC Compliance Report
Press Release: InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 Million and EBITDA of Over NIS 50 Million
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million -- Revenues for H2 2023 were affected by damages caused by the terrorist attack o
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg